ODC1 and neoplasm: Single DFMO agents exhibit restricted therapeutic efficacy in clinical tumors, and DFMO-mediated inhibition of ODC induces a compensatory mechanism whereby tumor cells augment the uptake of exogenous polyamines, including those present in the tumor microenvironment, dietary metabolites, microbiota, and particularly from decidualized or damaged cells in the intestinal lumen (24).